Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26328227 | 0.92 | CRBN (0.56) | CRBNDDB1KMT2AMEN1STAT3 | |
| SCHEMBL21965745 | 0.88 | CRBN (0.62) | CRBNDDB1 | |
| SCHEMBL26328245 | 0.86 | CRBN (0.49) | CRBNDDB1KMT2AMEN1MAPT | |
| SCHEMBL26328156 | 0.85 | CRBN (0.50) | CRBNDDB1C5AR1 | |
| SCHEMBL26328175 | 0.84 | CRBN (0.54) | CRBNDDB1 | |
| SCHEMBL26328133 | 0.82 | CRBN (0.47) | CRBNDDB1KMT2AMEN1MAPT | |
| SCHEMBL26328207 | 0.81 | CRBN (0.57) | CRBNDDB1KMT2AMEN1MAPT | |
| SCHEMBL26328169 | 0.80 | TRPV1 (0.38) | CRBNDDB1 | |
| SCHEMBL26328229 | 0.80 | DDB1 (0.45) | CRBNDDB1MAPT | |
| SCHEMBL26328204 | 0.80 | DDB1 (0.42) | CRBNDDB1C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885KMT2A 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.